×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ITRM – iterum therapeutics plc - ordinary share (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ITRM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
08:38 am
itrm
Iterum Therapeutics Regains Full Nasdaq Compliance [Yahoo! Finance]
High
Report
Iterum Therapeutics Regains Full Nasdaq Compliance [Yahoo! Finance]
11/21
08:30 am
itrm
Iterum Therapeutics Regains Full Nasdaq Compliance
Medium
Report
Iterum Therapeutics Regains Full Nasdaq Compliance
11/14
07:09 am
itrm
Iterum Therapeutics Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Iterum Therapeutics Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/14
07:00 am
itrm
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
Medium
Report
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
11/11
08:00 am
itrm
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Low
Report
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
10/28
05:00 am
itrm
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
High
Report
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
10/25
11:12 am
itrm
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections [Yahoo! Finance]
High
Report
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections [Yahoo! Finance]
10/25
11:03 am
itrm
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
High
Report
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
Date
Time
Symbol
Company Name
Action
%Chg
11/14/2024
07:00 am
ITRM
iterum therapeutics plc - ordinary share
MISS
Report
-4.9%
iterum therapeutics plc - ordinary share
8/14/2024
07:00 am
ITRM
iterum therapeutics plc - ordinary share
BEAT
Report
2.5%
iterum therapeutics plc - ordinary share
5/13/2024
07:00 am
ITRM
iterum therapeutics plc - ordinary share
BEAT
Report
-4.4%
iterum therapeutics plc - ordinary share
3/28/2024
07:00 am
ITRM
iterum therapeutics plc - ordinary share
BEAT
Report
-3.8%
iterum therapeutics plc - ordinary share
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
09:16 am
itrm
Form 8-K Iterum Therapeutics plc For: Nov 20
Low
Report
Form 8-K Iterum Therapeutics plc For: Nov 20
11/14
07:54 pm
itrm
Form SC 13G/A Iterum Therapeutics plc Filed by: Point72 Asset Management, L.P.
Low
Report
Form SC 13G/A Iterum Therapeutics plc Filed by: Point72 Asset Management, L.P.
11/14
03:32 pm
itrm
Form SC 13G Iterum Therapeutics plc Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G Iterum Therapeutics plc Filed by: ARMISTICE CAPITAL, LLC
11/14
07:31 am
itrm
Form 10-Q Iterum Therapeutics plc For: Sep 30
Medium
Report
Form 10-Q Iterum Therapeutics plc For: Sep 30
11/14
07:15 am
itrm
Form 8-K Iterum Therapeutics plc For: Nov 14
Medium
Report
Form 8-K Iterum Therapeutics plc For: Nov 14
11/1
05:10 pm
itrm
Form 8-K Iterum Therapeutics plc For: Oct 28
Medium
Report
Form 8-K Iterum Therapeutics plc For: Oct 28
10/30
06:24 am
itrm
Form 424B5 Iterum Therapeutics plc
High
Report
Form 424B5 Iterum Therapeutics plc
10/28
06:06 am
itrm
Form 424B5 Iterum Therapeutics plc
High
Report
Form 424B5 Iterum Therapeutics plc
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/26
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection
95.5%
12/11 Iterum Therapeutics PLC (NASDAQ: ITRM) was downgraded by analysts at Leerink Swann from an "outperform" rating to a "market perform" rating. 20.0%
4/27 Form PRE 14A Iterum Therapeutics plc For: Jun 10 15.4%
2/19 Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference 11.0%
12/1 Is Iterum Therapeutics plc (ITRM) Going To Burn These Hedge Funds ? [Yahoo! Finance News] 9.7%
3/16 Form S-8 Iterum Therapeutics plc 7.8%
11/18 Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection 6.0%
11/15 Iterum Therapeutics PLC (NASDAQ: ITRM) had its "buy" rating re-affirmed by analysts at G.Research, Llc. 4.7%
1/23 Form 4 Iterum Therapeutics plc For: Jan 21 Filed by: CANAAN X L.P. 3.8%
4/9 Iterum Therapeutics PLC (NASDAQ: ITRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 3.6%
12/11 Iterum Therapeutics PLC (NASDAQ: ITRM) was downgraded by analysts at Leerink Swann from an "outperform" rating to a "market perform" rating. 20.0%
4/27 Form PRE 14A Iterum Therapeutics plc For: Jun 10 15.4%
2/19 Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference 11.0%
12/1 Is Iterum Therapeutics plc (ITRM) Going To Burn These Hedge Funds ? [Yahoo! Finance News] 9.7%
3/16 Form S-8 Iterum Therapeutics plc 7.8%
11/18 Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection 6.0%
11/15 Iterum Therapeutics PLC (NASDAQ: ITRM) had its "buy" rating re-affirmed by analysts at G.Research, Llc. 4.7%
1/23 Form 4 Iterum Therapeutics plc For: Jan 21 Filed by: CANAAN X L.P. 3.8%
4/9 Iterum Therapeutics PLC (NASDAQ: ITRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 3.6%
TOP News Decliners
12/10
Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections
-37.0%
1/17 Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors -26.0%
3/13 Iterum Therapeutics PLC (NASDAQ: ITRM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. -19.3%
1/21 Iterum Therapeutics PLC (NASDAQ: ITRM) was downgraded by analysts at Gabelli from a "buy" rating to a "sell" rating. -13.5%
8/14 Form 8-K Iterum Therapeutics plc For: Aug 14 -11.0%
10/4 Iterum Therapeutics PLC (NASDAQ: ITRM) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -10.9%
3/12 Q4/2019 12/31/2019 EPS -1.590 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%
11/19 Iterum Therapeutics PLC (NASDAQ: ITRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.0%
1/22 Iterum Therapeutics PLC (NASDAQ: ITRM) was downgraded by analysts at G.Research, Llc from a "buy" rating to a "sell" rating. -8.3%
1/27 Form SC 13D/A Iterum Therapeutics plc Filed by: New Leaf Venture Management III, L.L.C. -7.1%
1/17 Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors -26.0%
3/13 Iterum Therapeutics PLC (NASDAQ: ITRM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. -19.3%
1/21 Iterum Therapeutics PLC (NASDAQ: ITRM) was downgraded by analysts at Gabelli from a "buy" rating to a "sell" rating. -13.5%
8/14 Form 8-K Iterum Therapeutics plc For: Aug 14 -11.0%
10/4 Iterum Therapeutics PLC (NASDAQ: ITRM) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -10.9%
3/12 Q4/2019 12/31/2019 EPS -1.590 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%
11/19 Iterum Therapeutics PLC (NASDAQ: ITRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.0%
1/22 Iterum Therapeutics PLC (NASDAQ: ITRM) was downgraded by analysts at G.Research, Llc from a "buy" rating to a "sell" rating. -8.3%
1/27 Form SC 13D/A Iterum Therapeutics plc Filed by: New Leaf Venture Management III, L.L.C. -7.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: